Search results for "Immunologic"

showing 10 items of 1115 documents

Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens

2006

Abstract Mycobacterium tuberculosis infects one-third of the global population and claims two million lives every year. Because memory CD8 T cells exhibit a high heterogeneity in terms of phenotype and functional characteristic, we investigated the frequency, phenotype, and functional properties of Ag85A epitope-specific HLA-A*0201 CD8 T cells in children affected by tuberculosis (TB) before and 4 mo after chemotherapy and healthy contact children. Using Ag85A peptide/HLA-A*0201 pentamer, we found a low frequency of blood peptide-specific CD8 T cells in tuberculous children before therapy, which consistently increased after therapy to levels detected in healthy contacts. Ex vivo analysis of…

MalePore Forming Cytotoxic ProteinsLEPROSYImmunologyEpitopes T-LymphocyteCD8-Positive T-LymphocytesBiologyTuberculinTUBERCULOSISEpitopeImmunophenotypingInterferon-gammaInterleukin 21Immune systemImmunophenotypingAntigenT-Lymphocyte SubsetsHLA-A2 AntigenHumansBACILLE CALMETTE-GUERINImmunology and AllergyCytotoxic T cellLymphocyte CountChildTuberculosis PulmonaryAntigens BacterialMembrane GlycoproteinsIFN-GAMMACOMPLEXHLA-A AntigensPerforinHIGH-FREQUENCIESMycobacterium tuberculosisINTRACELLULAR INFECTIONNatural killer T cellVirologyBOVIS BCGMICEChild PreschoolTuberculosis MeningealImmunologyFemaleImmunologic MemoryCD8RESPONSES
researchProduct

RAPID AND EFFICIENT ANTIGEN PROCESSING AND PRESENTATION OF A PROTECTIVE AND IMMUNODOMINANT HLA-B*27-RESTRICTED HEPATITIS C VIRUS-SPECIFIC CD8+T CELL …

2012

HLA-B*27 exerts protective effects in hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. While the immunological and virological features of HLA-B*27-mediated protection are not fully understood, there is growing evidence that the presentation of specific immunodominant HLA-B*27-restricted CD8+ T-cell epitopes contributes to this phenomenon in both infections. Indeed, protection can be linked to single immunodominant CD8+ T-cell epitopes and functional constraints on escape mutations within these epitopes. To better define the immunological mechanisms underlying HLA-B*27-mediated protection in HCV infection, we analyzed the functional avidity, functional profile, ant…

MaleProteasome Endopeptidase ComplexQH301-705.5Immune CellsAntigen presentationImmunologyAntigen-Presenting CellsAntigen Processing and RecognitionHepacivirusBiologyAdaptive ImmunityCD8-Positive T-LymphocytesMicrobiologyEpitopeImmune ActivationMajor Histocompatibility ComplexEpitopesImmune systemVirologyGeneticsCytotoxic T cellHumansAvidityBiology (General)Antigen-presenting cellMolecular BiologyBiologyAntigen PresentationLinear epitopeAntigen processingT CellsImmunityRC581-607VirologyHepatitis CHLA-B AntigensImmunologyProteolysisQR180ParasitologyFemaleImmunologic diseases. AllergyHepatitis C AntigensResearch Article
researchProduct

Characterization of rat glutathione transferases in olfactory epithelium and mucus

2019

International audience; The olfactory epithelium is continuously exposed to exogenous chemicals, including odorants. During the past decade, the enzymes surrounding the olfactory receptors have been shown to make an important contribution to the process of olfaction. Mammalian xenobiotic metabolizing enzymes, such as cytochrome P450, esterases and glutathione transferases (GSTs), have been shown to participate in odorant clearance from the olfactory receptor environment, consequently contributing to the maintenance of sensitivity toward odorants. GSTs have previously been shown to be involved in numerous physiological processes, including detoxification, steroid hormone biosynthesis, and am…

MaleProteomicsPhysiologyScienceMaterials ScienceEnzyme MetabolismRespiratory SystemResearch and Analysis MethodsBiochemistryOlfactory Receptor NeuronsOlfactory Mucosa[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyMedicine and Health SciencesGlutathione ChromatographyAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyAmino Acid SequenceRats Wistar[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansEnzyme ChemistryMaterialsImmunohistochemistry TechniquesGlutathione TransferaseAffinity ChromatographyChromatographic TechniquesQRBiology and Life SciencesProteinsGlutathioneImmunohistochemistryBody FluidsEnzymesRatsHistochemistry and Cytochemistry TechniquesMucusNasal Mucosa[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansAmino Acid Specific ChromatographyPhysical SciencesOdorantsEnzymologyImmunologic TechniquesMedicineAnatomyPeptidesResearch Article
researchProduct

A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple s…

2016

Abstract Introduction Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. Methods POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale – Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure…

MalePsychometricsAnxietyHospital Anxiety and Depression Scale0302 clinical medicineImmunologic FactorMultiple sclerosis Disease-modifying treatment Emotional burden Anxiety DepressionMultiple SclerosiDisease-modifying treatment030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)DepressionMiddle AgedPsychiatric Status Rating ScaleTreatment OutcomeItalyNeurologyAnxietyFemaleSettore MED/26 - Neurologiamedicine.symptomPsychologyPsychometricHumanAdultmedicine.medical_specialtyMultiple SclerosisMood DisorderPsychometricsAdolescentLogistic Model03 medical and health sciencesYoung AdultRating scalemedicineHumansImmunologic FactorsAgedPsychiatric Status Rating ScalesMood Disordersmedicine.diseaseProspective StudieLogistic ModelsMood disordersPhysical therapyEmotional burdenObservational studyNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

2005

Background The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years. Objective To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years. Methods Sixty-five children (51 boys and 14 girls; age range, 38-80 months; mean ± SD age, 60 ± 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were ho…

MalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyParietariaImmunologyAdministration SublingualSublingual administrationImmunopathologyAge Factors; Conjunctivitis Allergic; Humans; Allergens; Asthma; Rhinitis; Child; Desensitization Immunologic; Administration Sublingual; Male; Female; Child PreschoolHumansImmunology and AllergyMedicineAge FactorChildRhinitiRhinitisConjunctivitis Allergicbiologybusiness.industryCumulative doseAllergenAge FactorsAllergensbiology.organism_classificationAsthmaDiscontinuationClinical trialEl NiñoDesensitization ImmunologicChild PreschoolFemaleObservational studybusinessHumanAnnals of Allergy, Asthma & Immunology
researchProduct

Adherence to immunomodulatory drugs in patients with multiple myeloma

2018

Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomi…

MaleQuestionnairesCancer Treatment030204 cardiovascular system & hematologyPharmacistsPlasma Cell DisordersHematologic Cancers and Related DisordersMathematical and Statistical Techniques0302 clinical medicineSurveys and QuestionnairesMedicine and Health SciencesMedical PersonnelProspective StudiesProspective cohort studyMultiple myelomaMultidisciplinaryQStatisticsRHematologyMyelomasProfessionsOncologyResearch Design030220 oncology & carcinogenesisPhysical SciencesMedicineRegression AnalysisFemaleMultiple MyelomaResearch Articlemedicine.drugmedicine.medical_specialtyDrug AdherenceClinical Research DesignScienceLinear Regression AnalysisResearch and Analysis MethodsMedication Adherence03 medical and health sciencesCronbach's alphaInternal medicinemedicineHumansImmunologic FactorsIn patientMyelomas and Lymphoproliferative DiseasesStatistical MethodsAdverse effectAgedLenalidomidePharmacologySurvey Researchbusiness.industryCancers and NeoplasmsPomalidomidemedicine.diseaseThalidomidePeople and PlacesPopulation GroupingsAdverse EventsbusinessMathematicsPLOS ONE
researchProduct

A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area

2020

Background Data on the true prevalence of hepatitis C virus (HCV) infection in the general population is essential. We evaluated a program implementing free universal HCV screening using a non-invasive point-of-care test (POCT) (OraQuick-HCV rapid test) in oral fluid in an urban area in Valencia, South-Eastern Spain. Methods A cross-sectional study was performed during 2015–2017. Free HCV screening was offered by regular mail to 11,500 individuals aged 18 and over, randomly selected from all census residents in the Health Department. All responding participants filled in a questionnaire about HCV infection risk factors and were tested in their tertiary Hospital. In those with a positive POC…

MaleRNA virusesSustained Virologic ResponseUrban PopulationEpidemiologyPhysiologyCross-sectional studyHepacivirusmedicine.disease_causeBiochemistryGeographical locations0302 clinical medicineRisk FactorsImmune PhysiologyPrevalence030212 general & internal medicineEnzyme-Linked ImmunoassaysYoung adultPathology and laboratory medicineAged 80 and overResponse rate (survey)education.field_of_studyImmune System ProteinsMultidisciplinaryHepatitis C virusQRMiddle AgedMedical microbiologyHepatitis CEuropeVirusesRNA ViralMedicineFemale030211 gastroenterology & hepatologyStandardized ratePathogensResearch ArticleAdultmedicine.medical_specialtyAdolescentPoint-of-Care SystemsScienceHepatitis C virusPoint-of-care testingImmunologyPopulationResearch and Analysis MethodsAntiviral AgentsMicrobiologyAntibodiesYoung Adult03 medical and health sciencesInternal medicinemedicineHumansEuropean UnionRisk factorImmunoassayseducationAgedMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryOrganismsViral pathogensProteinsHepatitis C AntibodiesFibrosisHepatitis virusesMicrobial pathogensHealth CareCross-Sectional StudiesSpainMedical Risk FactorsImmunologic TechniquesInterferonsPeople and placesbusinessDevelopmental BiologyPLOS ONE
researchProduct

MHC-restricted T cell receptor signaling is required for αβ TCR replacement of the pre T cell receptor

2008

A developmental block is imposed on CD25(+)CD44(-) thymocytes at the beta-selection checkpoint in the absence of the pre T cell receptor (preTCR) alpha-chain, pTalpha. Early surface expression of a transgenic alphabeta TCR has been shown to partially circumvent this block, such that thymocytes progress to the CD4(+)CD8(+) double-positive stage. We wanted to analyze whether a restricting MHC element is required for alphabeta TCR-expressing double-negative (DN) thymocytes to overcome the developmental block in pTalpha-deficient animals. We used the HY-I knock-in model that endows thymocytes with alphabeta TCR expression in the DN compartment but has the advantage of physiological expression l…

MaleReceptors Antigen T-Cell alpha-betaT-LymphocytesT cellH-Y AntigenImmunologyMice Transgenicchemical and pharmacologic phenomenaBiologyMajor histocompatibility complexMicemedicineAnimalsImmunology and AllergyCytotoxic T cellIL-2 receptorHistocompatibility Antigen H-2DReceptorMice KnockoutMice Inbred BALB CMembrane GlycoproteinsLymphopoiesisT-cell receptorH-2 AntigensModels Immunologicalhemic and immune systemsMHC restrictionMolecular biologymedicine.anatomical_structurebiology.proteinFemaleCD8Signal TransductionEuropean Journal of Immunology
researchProduct

Analysis of memory and effector CD8+ T cell subsets in chronic graft-versus-host disease.

2009

In humans, the selective depletion of CD8+ cells may prevent GVHD after allogeneic transplantation. These cells can infiltrate and damage target tissues. It is of interest to investigate the phenotypical characteristics and cytotoxic properties of the different CD8+ subsets in cGVHD patients. In a preliminary study we found that patients with cGVHD had a markedly elevated percentage of peripheral blood CCR7−/CD45RA+ cells compared to patients without cGVHD; conversely, the CCR7+/CD45RA+ subsets of CD8+ cells was significantly decreased. In this study, we report in depth on the phenotype of effector T cell subsets in cGVHD patients, as well as their proliferative capability, cytotoxic prope…

MaleReceptors CCR7T cellImmunologyGraft vs Host DiseaseC-C chemokine receptor type 7CD8-Positive T-LymphocytesLymphocyte ActivationGranzymesimmune system diseasesmedicineImmunology and AllergyCytotoxic T cellHumansAgedPharmacologybiologyEffectorChemistryPerforinMiddle Agedmedicine.diseaseGraft-versus-host diseasemedicine.anatomical_structureGranzymePerforinImmunologyChronic Diseasebiology.proteinLeukocyte Common AntigensFemaleImmunologic MemoryCD8International journal of immunopathology and pharmacology
researchProduct

Induction of RAGE Shedding by Activation of G Protein-Coupled Receptors

2011

The multiligand Receptor for Advanced Glycation End products (RAGE) is involved in various pathophysiological processes, including diabetic inflammatory conditions and Alzheimers disease. Full-length RAGE, a cell surface-located type I membrane protein, can proteolytically be converted by metalloproteinases ADAM10 and MMP9 into a soluble RAGE form. Moreover, administration of recombinant soluble RAGE suppresses activation of cell surface-located RAGE by trapping RAGE ligands. Therefore stimulation of RAGE shedding might have a therapeutic value regarding inflammatory diseases. We aimed to investigate whether RAGE shedding is inducible via ligand-induced activation of G protein-coupled recep…

MaleReceptors Vasopressinendocrine system diseasesReceptor for Advanced Glycation End Productslcsh:MedicineHydroxamic Acids570 Life sciencesRAGE (receptor)Adenylyl cyclaseADAM10 ProteinMicePhosphatidylinositol 3-Kinaseschemistry.chemical_compoundMolecular Cell BiologyNeurobiology of Disease and RegenerationSignaling in Cellular ProcessesMembrane Receptor SignalingReceptors Immunologiclcsh:ScienceReceptorLungCellular Stress ResponsesCalcium signalingMultidisciplinaryKinaseDipeptidesHormone Receptor SignalingCell biologyMatrix Metalloproteinase 9NeurologyReceptors OxytocinGene Knockdown Techniquescardiovascular systemMatrix Metalloproteinase 2Pituitary Adenylate Cyclase-Activating PolypeptideMedicineRNA InterferenceAdenylyl CyclasesResearch ArticleSignal Transduction570 Biowissenschaftenmedicine.medical_specialtyMAP Kinase Signaling SystemADAM17 ProteinBiologyAlzheimer DiseaseCa2+/calmodulin-dependent protein kinaseInternal medicinemedicineAnimalsHumansProtease InhibitorsCalcium Signalingcardiovascular diseasesBiologyG protein-coupled receptorlcsh:RHEK 293 cellsMembrane Proteinsnutritional and metabolic diseasesCyclic AMP-Dependent Protein KinasesADAM ProteinsG-Protein SignalingHEK293 CellsEndocrinologychemistryProteolysisDementialcsh:QAmyloid Precursor Protein SecretasesMolecular Neurosciencehuman activitiesReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type INeurosciencePLoS ONE
researchProduct